The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Novikova K.V.

Department of Neurology, Neurusurgery and Medical Genetics of the Medical Faculte, Pirogov Russian National Research Medical University, Moscow, Russia

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Konovalova O.E.

Interregional Department of Multiple Sclerosis at Moscow Clinical Hospital №24, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Kozhieva M.Kh.

Pirogov Russian National Research Medical University, Moscow, Russia

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy

Authors:

Popova E.V., Novikova K.V., Khachanova N.V., Konovalova O.E., Kozhieva M.Kh., Davydovskaya M.V., Boĭko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10‑2): 48‑52

DOI: 10.17116/jnevro201711710248-52

Read: 1543 times

Contact the author
Table of contents

THE SEARCH FOR OPTIMAL DECISION IN THE TREATMENT OF MULTIPLE SCLEROSIS: TO IMPROVE ADHERENCE NOT REDUCING THE EFFICACY
THE SEARCH FOR OPTIMAL DECISION IN THE TREATMENT OF MULTIPLE SCLEROSIS: TO IMPROVE ADHERENCE NOT REDUCING THE EFFICACY

To cite this article:

Popova EV, Novikova KV, Khachanova NV, Konovalova OE, Kozhieva MKh, Davydovskaya MV, Boĭko AN. The search for optimal decision in the treatment of multiple sclerosis: to improve adherence not reducing the efficacy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(10‑2):48‑52. (In Russ.)
https://doi.org/10.17116/jnevro201711710248-52

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Long-term disease modifying therapy (DMD) therapy is the basis of modern MS treatment, effiecacy of which is modulated by the patient’s adherence to therapy. One of the possible solutions of low adherence improvement is the use of innovative drugs and the development of more convenient regimens of injectable medications. This article gives a brief review of peg-interferon β-1a clinical trials.

Keywords:

multiple sclerosis
DMT
peg-interferon β-1a
adherence

Authors:

Popova E.V.

Kafedra nervnykh bolezneĭ fakul'teta poslevuzovskogo professional'nogo obrazovaniia vracheĭ Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Novikova K.V.

Department of Neurology, Neurusurgery and Medical Genetics of the Medical Faculte, Pirogov Russian National Research Medical University, Moscow, Russia

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Konovalova O.E.

Interregional Department of Multiple Sclerosis at Moscow Clinical Hospital №24, Moscow, Russia;
Pirogov Russian National Research Medical University, Moscow, Russia

Kozhieva M.Kh.

Pirogov Russian National Research Medical University, Moscow, Russia

Davydovskaya M.V.

Research and Practical Centre for Clinical Investigations and Evaluation of Medical Technologies, Moscow Health Department, Moscow, Russia

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Close metadata

References:

  1. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Multiple Sclerosis Journal. 2008;14(5):640-655. https://doi.org/10.1177/1352458507086463
  2. Annibali V, Mechelli R, Romano S, et al. IFN-β and multiple sclerosis: From etiology to therapy and back. Cytokine & Growth Factor Reviews. 2015;26(2):221-228. https://doi.org/10.1016/j.cytogfr.2014.10.010
  3. Giovannoni G, Tomic D, Bright J, Havrdová E. «No evident disease activity»: The use of combined assessments in the management of patients with multiple sclerosis. Multiple Sclerosis Journal. 2017:135245851770319. https://doi.org/10.1177/1352458517703193
  4. Incorporating Personalized Patient Management Strategies into the Treatment of Multiple Sclerosis. Multiple Sclerosis and Related Disorders. 2016;7:113. https://doi.org/10.1016/j.msard.2016.03.018
  5. Yamout B. Diagnosis and treatment of multiple sclerosis: MENACTRIMS consensus guidelines. Multiple Sclerosis and Related Disorders. 2014;3(6):766. https://doi.org/10.1016/j.msard.2014.09.010
  6. Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285. https://doi.org/10.1212/wnl.45.7.1277
  7. Johnson K, Brooks B, Cohen J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 1995;45(7):1268-1276. https://doi.org/10.1212/wnl.45.7.1268
  8. Jacobs L, Cookfair D, Rudick R, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Annals of Neurology. 1996;39(3):285-294. https://doi.org/10.1002/ana.410390304
  9. Rudick R, Simonian N, Alam J, et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology. 1998;50(5):1266-1272. https://doi.org/10.1212/wnl.50.5.1266
  10. Ebers G. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. The Lancet. 1998;352(9139): 1498-1504. https://doi.org/10.1016/s0140-6736(98)03334-0
  11. Kieseier B, Calabresi P. PEGylation of Interferon-β-1a. CNS Drugs. 2012;26(3):205-214. https://doi.org/10.2165/11596970-000000000-00000
  12. Oh J, O’Connor P. Novel and imminently emerging treatments in relapsing — remitting multiple sclerosis. Current Opinion in Neurology. 2015;28(3):230-236. https://doi.org/10.1097/wco.0000000000000203
  13. Kieseier B. The challenges of measuring disability accumulation in relapsing—remitting multiple sclerosis: evidence from interferon beta treatments. Expert Review of Neurotherapeutics. 2014;14(1):105-120. https://doi.org/10.1586/14737175.2014.869478
  14. National Multiple Sclerosis Society, USA. National Multiple Sclerosis Society. Disease Management Consensus Statement. [Internet]. http://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/ExpOp_Consensus.pdf
  15. Teva Neuroscience. Copaxone US Prescribing Information. [Internet]. https://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf
  16. Biogen Idec Inc., USA. Avonex US Prescribing Information. [Internet]. http://www.avonex.com/pdfs/guides/Avonex_Prescribing_Information.pdf
  17. Mohr D, Boudewyn A, Likosky W, Levine E, Goodkin D. Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and infection anxiety on adherence and ability to self-inject. Annals of Behavioral Medicine. 2001;23(2):125-132. https://doi.org/10.1207/s15324796abm2302_7
  18. White J, Newsome S, Kieseier B, et al. Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Therapeutic Advances in Neurological Disorders. 2016;9(4):239-249. https://doi.org/10.1177/1756285616633967
  19. World Health Organisation. Adherence to longterm therapies, evidence for action. http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf
  20. Devonshire V, Lapierre Y, Macdonell R, et al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology. 2010;18(1):69-77. https://doi.org/10.1111/j.1468-1331.2010.03110.x
  21. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Preference and Adherence. 2010:1. https://doi.org/10.2147/ppa.s8230
  22. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Preference and Adherence. 2011;73. https://doi.org/10.2147/ppa.s15702
  23. Tremlett H, Oger J. Interrupted therapy: Stopping and switching of the -interferons prescribed for MS. Neurology. 2003;61(4):551-554. https://doi.org/10.1212/01.wnl.0000078885.05053.7d
  24. Edgar C, Brunet D, Fenton P, McBride E, Green P. Lipoatrophy in Patients with Multiple Sclerosis on Glatiramer Acetate. The Canadian Journal of Neurological Sciences. 2004;31(01):58-63. https://doi.org/10.1017/s0317167100002845
  25. Soоs N, Shakery K, Mrowietz U. Localized Panniculitis and Subsequent Lipoatrophy with Subcutaneous Glatiramer Acetate (Copaxone) Injection for the Treatment of Multiple Sclerosis. American Journal of Clinical Dermatology. 2004;5(5):357-359. https://doi.org/10.2165/00128071-200405050-00009
  26. Torkildsen О, Myhr K, Bø L. Disease-modifying treatments for multiple sclerosis — a review of approved medications. European Journal of Neurology. 2015;23:18-27. https://doi.org/10.1111/ene.12883
  27. Khan U, Tanasescu R, Constantinescu C. PEGylated IFNβ-1a in the treatment of multiple sclerosis. Expert Opinion on Biological Therapy. 2015;15(7):1077-1084. https://doi.org/10.1517/14712598.2015.1053206
  28. Sorensen P, Deisenhammer F, Duda P, et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. European Journal of Neurology. 2005;12(11):817-827. https://doi.org/10.1111/j.1468-1331.2005.01386.x
  29. Paolicelli D, Manni A, Iaffaldano A, et al. The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study. European Journal of Clinical Pharmacology. 2016;72(8):1025-1029. https://doi.org/10.1007/s00228-016-2073-6
  30. Sorensen P. Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away? European Journal of Neurology. 2009;16(1):1-2. https://doi.org/10.1111/j.1468-1331.2008.02265.x
  31. European Medicines Agency. Plegridy: assessment report. Procedure No. EMEA/H/C/002827/0000. [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002827/WC500170303.pdf
  32. European Medicines Agency. Plegridy solution for injection: summary of product characteristics. [Internet]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002827/WC500170302.pdf
  33. Calabresi P, Kieseier B, Arnold D, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. The Lancet Neurology. 2014;13(7):657-665. https://doi.org/10.1016/s1474-4422(14)70068-7
  34. Kieseier B, Arnold D, Balcer L, et al. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Multiple Sclerosis Journal. 2015;21(8):1025-1035. https://doi.org/10.1177/1352458514557986
  35. Lyseng-Williamson K, Hoy S. Peginterferon beta-1a in relapsing — remitting multiple sclerosis: a guide to its use in the EU. Drugs & Therapy Perspectives. 2015;31(6):190-195. https://doi.org/10.1007/s40267-015-0216-y
  36. Arnold D, Calabresi P, Kieseier B, et al. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis. BMC Neurology. 2014;14(1). https://doi.org/10.1186/s12883-014-0240-x
  37. Cocco E, Marrosu M. Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis. Therapeutics and Clinical Risk Management. 2015;759. https://doi.org/10.2147/tcrm.s69123
  38. Tolley K, Hutchinson M, You X, et al. A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLOS ONE. 2015;10(6):e0127960. https://doi.org/10.1371/journal.pone.0127960
  39. Coyle PK, Shang S, You, Castrillo-Viguera C, Fiore D. SC Peginterferon Beta-1a Every 2 Weeks Demonstrated Better Clinical Outcomes than SC Interferon Beta-1aTIW in Patients with RMS, Using a Matching-Adjusted Comparison of 6 Phase 3 Trials.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.